Extensive data on patients’ natural history of relapsing after surgery and after curative radiotherapy indicate that the PSA doubling time (PSADT) predicts the probability of metastasis-free and prostate cancer-specific survival [5,6,7,8,9,10,11]. Here, KLK3 is linked to prostate carcinoma.